What Nifelat R Treats: Main Uses and Benefits

Nifelat R (Nifedipine extended-release) is applied across domains where additional symptomatic support is needed for the management of conditions marked by increased pressure. It is commonly used in conditions characterized by periods of heightened symptoms that may interfere with daily functioning.

---

Key Therapeutic Applications

This medication is commonly used for the long-term management of conditions presenting with systemic imbalance and symptoms related to physical discomfort. Its applications primarily involve managing Hypertension (chronic high blood pressure) and Angina Pectoris (chronic stable angina and vasospastic angina), and it is considered relevant for easing Peripheral Circulatory Distress like Raynaud's phenomenon. This treatment provides assistance in situations requiring supportive symptom management.

The use of this medication may assist with managing functional stress linked to high pressure and contributes to improved comfort during physical activity. This continuous control contributes to easing the overall symptom load and supports general well-being during symptomatic periods.

Quick Fact: Relief for Chronic Vasoconstriction
Nifelat R may assist with managing the frequency and intensity of symptoms related to localized vascular constriction, helping to maintain functional stability.

Regulatory References

1. NIH MedlinePlus overview

Who Can and Cannot Use Nifelat R? (Nifedipine Extended-Release)

The eligibility for Nifelat R is defined by official regulatory labeling, which establishes specific populations who are permitted to use the medicine, who must not use it, and who require restricted use.

Contraindications: Who Must Not Use Nifelat R

Use of Nifelat R is contraindicated and must not be used in patients with a known hypersensitivity to Nifedipine or any related dihydropyridine derivative. It is also prohibited for patients in Cardiogenic Shock, those taking the strong CYP3A4 inducer Rifampin, or individuals with severe or mechanical Bowel Obstruction.

Age and Organ-Function Eligibility

Population Group	Regulatory Status
Pediatric Patients (<18 years)	Use is not recommended; safety and efficacy are not established.
Older Adults (Geriatric)	Use requires caution due to a greater likelihood of age-related organ impairment.
Hepatic Impairment (Liver)	Use requires caution and close monitoring; dose adjustment may be necessary.

Pregnancy and Lactation

Use during pregnancy and lactation is contraindicated according to some official regulatory documents. Use is advised only if the potential benefit justifies the potential risk, depending on regional labeling. The drug is intended for use only by adult populations (18 years and older) who do not have any contraindications.

Interactions with other medicines and products

Nifelat R (nifedipine) interacts with other medicinal products primarily through its metabolism by the CYP3A4 enzyme system and through pharmacodynamic effects on blood pressure.

Contraindicated and Restricted Combinations

Classification	Interacting Agents (Examples)	Summary of Interaction
Contraindicated	Rifampicin	Significantly reduces nifedipine concentration due to CYP3A4 induction, leading to loss of therapeutic effect. This combination must be avoided.
Avoid	Grapefruit or Grapefruit Juice	Inhibits CYP3A4, causing a substantial increase in nifedipine levels, raising the risk of adverse effects.

---

Use with Caution and Monitoring

Co-administration with other blood pressure lowering agents (such as diuretics, beta-blockers, or ACE inhibitors like enalapril) requires careful blood pressure monitoring due to an increased risk of severe hypotension (low blood pressure).

CYP3A4 Inhibitors (e.g., macrolide antibiotics like erythromycin and clarithromycin, azole antifungals like fluconazole and itraconazole, or cimetidine) can raise nifedipine levels, necessitating the use of the lowest effective Nifelat R dose and close observation for adverse effects.

CYP3A4 Inducers (e.g., antiepileptics like phenytoin or carbamazepine, or the herbal product St. John's wort) can reduce nifedipine concentrations and should generally be avoided or used with caution under medical supervision.

Monitoring of serum levels is required for Digoxin (due to potential for elevated levels) and when Nifelat R is used concurrently with coumarin anticoagulants (due to rare reports of altered prothrombin time).

Inhibition of Vascular Calcium Channels

The core mechanism of Nifelat R, which contains Nifedipine, is the highly selective inhibition of L-type voltage-gated calcium channels ( CaV1.2) present on the cell membranes of peripheral vascular smooth muscle. This action prevents the influx of calcium ions ( Ca^2+) needed to initiate muscle contraction. This modulation is voltage-dependent, meaning it preferentially targets and stabilizes the channels in the inactivated state characteristic of highly depolarized vascular smooth muscle.

Direct Modulation of Arterial Tone

By restricting the entry of Ca^2+, Nifelat R disrupts the cellular excitation-contraction coupling sequence, leading to the relaxation, or vasodilation, of the arterial walls. This mechanistic cascade is responsible for lowering the Total Peripheral Vascular Resistance (PVR), which is the resistance force generated by the peripheral vasculature against cardiac output.

Modulation of Cardiac Afterload

The widespread reduction in PVR is the key systemic consequence of Nifelat R's mechanism. This reduction directly decreases the afterload—the pressure and resistance against which the heart contracts—thereby modulating the energetic requirements of the myocardium. Furthermore, the mechanism also promotes relaxation in the coronary arteries, leading to increased vessel diameter and blood flow within the myocardium.

Official Administration Guidelines for Nifelat R

Nifelat R (Nifedipine Extended-Release) is intended for oral administration and is structured for chronic, long-term management. The extended-release design requires strict adherence to the prescribed usage methodology to ensure the medicine is released slowly and consistently over a 24-hour period.

Dosing and Schedule

The standard adult dosing schedule for Nifelat R is once daily. The typical initial dose is either 30 mg or 60 mg, taken at approximately the same time each day. The usual daily maintenance dose may range from 30 mg up to 90 mg, although some labels cite a maximum daily dose of 120 mg. Dose adjustments, or titration, are performed gradually, generally requiring a period of 7 to 14 days between changes to fully assess the body's response.

Procedural Instructions and Constraints

The tablet must be swallowed whole with water and must not be broken, crushed, or chewed under any circumstances. Altering the tablet's physical form disrupts the controlled-release mechanism. Nifelat R can be taken with or without food, but administration should remain consistent from day to day. Patients may occasionally notice the insoluble outer shell of the tablet (the matrix) in their stool, which indicates the drug delivery system has functioned correctly.

Population-Specific Instructions

Labeling requires special consideration for certain patient groups. For individuals with hepatic impairment, therapy should be initiated with caution, and starting with the lowest available dose (e.g., 30 mg) is advised. While dose adjustments are not usually required for renal impairment, lower maintenance doses may be necessary for older adults. Nifelat R is generally not recommended for use in children under 18 years of age.

Research evidence / Overview of Studies for Nifelat R

The research evidence for Nifelat R focuses on its use in chronic conditions where reducing peripheral vascular resistance is a primary goal. The evidence base primarily consists of Randomized Controlled Trials (RCTs), Systematic Reviews, and large Observational Studies that describe patient patterns over time.

---

Evidence for Use in Chronic High Blood Pressure (Hypertension)

Studies for chronic high blood pressure include numerous RCTs comparing the compound against a placebo or other active medications. Research monitored systolic and diastolic blood pressure as primary outcomes over defined time intervals. Studies reported patterns related to blood pressure measurements, and meta-analyses focusing on long-term outcomes monitored patients over a decade.

Long-term effects are not fully established based solely on the original, short-term efficacy trials. An important limitation is that some older research included immediate-release formulations of the active ingredient, which were associated with different release characteristics and clinical patterns.

Evidence for Use in Angina Pectoris

Studies explored the evidence base for Nifelat R in chronic stable angina and vasospastic angina. The research primarily focused on short-term RCTs that evaluated outcomes related to episodic or acute changes. Researchers monitored patient-reported outcomes describing perceived discomfort and measured activity level.

The original controlled trials provided limited information for long-term outcomes in this population, as follow-up durations were often limited to several weeks for efficacy. Regulators have noted that confirmation of sustained effectiveness and the long-term patterns related to major cardiovascular events remains incomplete from the initial controlled research.

Evidence for Use in Peripheral Circulatory Distress (Raynaud's Phenomenon)

Research examined this compound in short-term RCTs, often using a crossover design. Studies focused on outcomes related to episodic changes, such as a reduction in the number of vasospastic attacks, and patient-reported outcomes describing intensity. Findings indicate that this compound may be associated with changes in subjective outcomes, though the findings were mixed for some objective measures.

Data for long-term outcomes are still emerging, as most research focused on short-term symptom relief, with follow-up periods rarely exceeding 20 weeks.

Common questions about Nifelat R (FAQ)

Q: How does Nifelat R differ from standard Nifelat?

Nifelat R is the extended-release (ER) formulation of the active ingredient, Nifedipine. This formulation uses a specialized design to release the medicine slowly and consistently over approximately 24 hours. This sustained delivery method is what distinguishes it from immediate-release (standard) formulations.

Q: Are there any specific foods or drinks I should avoid while on Nifelat R?

Regulatory documents strongly advise that patients avoid or limit grapefruit and grapefruit juice. Official product information indicates that these products have been observed to increase the level of the medicine in the blood, which is associated with a greater risk of adverse effects.

Q: How does Nifelat R affect the heart rate?

Official safety documents report that Nifelat R may cause tachycardia (an increased heart rate) or palpitations (a noticeable or irregular heartbeat) as a potential side effect. These are listed as common or uncommon adverse reactions in official labeling.

Q: Are there any long-term health concerns associated with using Nifelat R?

One adverse effect, gynaecomastia (an enlargement of breast tissue in males), has been reported in association with long-term therapy. Other known long-term side effects that may require management include edema (swelling) of the legs.

Q: Are there any known interactions between Nifelat R and herbal remedies?

Yes, regulatory documents indicate that Nifelat R should not be used in combination with the herbal product St. John's wort (Hypericum perforatum). Official safety information indicates that this herb may reduce the level and effectiveness of the medicine in the body.

Q: Is Nifelat R commonly used in combination with other medicines for the same condition?

Nifelat R is often used cautiously with other blood pressure lowering agents such as beta-blockers or diuretics. Regulatory documents indicate that co-administration is associated with an increased risk of severe low blood pressure (hypotension), and therefore monitoring may be necessary.

Q: Is Nifelat R used to prevent a specific medical event?

Official labeling defines the medicine as indicated for the management of chronic conditions, such as hypertension and angina. The research evidence notes limitations in confirming long-term outcomes related to the prevention of major cardiovascular events.

Q: What should I be careful about when driving while taking Nifelat R?

Official product information notes that caution is warranted when operating machinery or driving. Side effects like dizziness, lightheadedness, or feeling faint may impair your ability to react, especially when treatment begins, when the dose is increased, or when the medicine is combined with alcohol.

Q: What happens if I miss a dose of Nifelat R?

Patient information commonly describes that if a dose is missed, the recommended procedure is to take it as soon as it is remembered, unless it is almost time for the next scheduled dose (typically less than 12 hours before). If so, the missed dose should be skipped. It is further noted that patients should avoid taking a double dose to make up for the missed one.

Q: Is it safe to take over-the-counter pain relievers like ibuprofen with Nifelat R?

Regulatory information indicates that concurrent use of Nifelat R with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen, may lead to an undesirable increase in blood pressure. The regulatory documents indicate that monitoring of blood pressure may be needed for this combination.

Q: Does Nifelat R interact with supplements like magnesium or calcium?

Official drug interaction databases report that Nifedipine may interact with certain multivitamins with minerals. Taking them together has been noted to potentially necessitate blood pressure monitoring.

Q: What are the official warnings about combining Nifelat R with alcohol?

Official warnings state that alcohol may have additive effects in lowering blood pressure when combined with Nifelat R. This is because both can cause vasodilation, increasing the risk of side effects like dizziness, lightheadedness, or fainting.

Q: What should I do if the side effects of Nifelat R are bothering me?

Official patient information consistently advises that the process for managing persistent, bothersome, or concerning symptoms is to contact a healthcare professional (such as a doctor or pharmacist) for guidance.

Q: Is Nifelat R considered a controlled substance?

No, Nifelat R, which contains Nifedipine, is not classified as a controlled substance under the US Drug Enforcement Administration (DEA) Schedule. It is classified as a prescription-only medicine.

Q: Do studies suggest Nifelat R is generally well-tolerated?

Studies on the extended-release formulation suggest it is generally associated with better tolerance than immediate-release forms. However, the official adverse effect profile indicates that common side effects, primarily related to its blood vessel widening action, affect a percentage of patients.

Q: What is the typical time frame for the effects of Nifelat R to wear off after a dose?

The extended-release formulation is specifically designed to maintain an approximately constant release rate over 24 hours. This ensures steady therapeutic levels in the bloodstream throughout the day.

Q: Can Nifelat R affect my sleep or cause insomnia?

Official labeling reports sleep disturbances or nervousness as uncommon adverse reactions in the psychiatric and nervous system disorders classifications.

Q: What does the 'R' stand for in Nifelat R?

The 'R' in Nifelat R is commonly used in pharmaceutical naming to denote a Retard or Release formulation. This signifies the medicine's extended- or slow-release design (Nifedipine Retard/Extended Release).

Q: Does Nifelat R have a 'black box' warning from the FDA?

No, the approved extended-release formulation of Nifedipine does not have an FDA-mandated black box warning. Black box warnings are the strongest safety warnings the FDA requires for prescription drugs.

Q: Does Nifelat R cause any changes to vision?

Official adverse reaction lists include visual disturbances as an uncommon or rare side effect in the eye disorders classification.

Q: How quickly can I stop taking Nifelat R if I feel better?

Regulatory guidance explicitly notes that patients are advised not to stop taking Nifelat R abruptly. Abrupt discontinuation, particularly after prolonged use, may lead to rebound effects such as a sudden increase in angina or hypertension.

Q: Are there any official recommendations about sunlight exposure while taking Nifelat R?

Official safety data indicates that Nifedipine has been rarely associated with photosensitivity reactions. Due to this association, regulatory information suggests caution or avoidance of excessive sunlight or ultraviolet (UV) light exposure may be warranted.

Q: Is Nifelat R available as a generic medicine?

Yes, Nifedipine extended-release is widely available in the US and internationally as an approved generic medicine. This status is indicated in official marketing documents.

Q: Are there any blood tests required before starting Nifelat R?

While routine baseline tests for all patients are not specified, the use of Nifelat R requires periodic monitoring of liver function (blood tests) in patients with existing hepatic (liver) impairment to assess safety.

Q: Can Nifelat R affect my mood or cause depression?

Official labeling includes mood changes, nervousness, and in some regulatory documents, anxiety or depression as uncommon or rare side effects. These effects are classified under psychiatric and nervous system disorders.

How to Store and Dispose of Nifelat R

The storage and disposal of Nifelat R (nifedipine extended-release) must strictly adhere to official regulatory requirements to maintain product stability and ensure safety.

---

Official Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature (20°C to 25°C or 68°F to 77°F).
Protection	The tablets must be protected from light and moisture.
Container	Keep the medicine in the original container, tightly closed.
Safety	Keep this and all medication out of the reach of children.

---

Disposal Instructions

Unused or expired Nifelat R must be disposed of according to local regulations. The preferred method is using a community drug take-back program or authorized collection site. If these are unavailable, official guidelines state that the drug should be mixed with an undesirable substance (e.g., used coffee grounds) and placed in a sealed bag before discarding in the household trash. The medication must not be flushed down the toilet or disposed of in wastewater.